AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Change in Fair Value of Contingent Consideration by Year
Change in Fair Value of Contingent Consideration — Diluted EPS Impact ($/sh) ($)
AbbVie Change in Fair Value of Contingent Consideration: $3.56 in FY2025, up 72.0% from a year earlier.
Where the FY2025 figure comes from
“|| Change in fair value of contingent consideration | 6,495 | 6,309 | 3.56”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Non-GAAP Reconciliations.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Change in Fair Value of Contingent Consideration — Diluted EPS Impact ($/sh) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.56 | +72.0% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 2.07 | -26.3% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 2.81 | +81.3% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 1.55 | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie Change in Fair Value of Contingent Consideration ($), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap-spec-cc-eps
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.